- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Digital Therapeutics Alliance Product Library and Evaluation Toolkit
DTA is convening a broad coalition of stakeholders to advance the industry.
Their collective efforts are improving clinical and health economic outcomes through the use of high quality, evidence-based digital therapeutics for patients, clinicians, and payors.
DTA's cross-industry coalition is comprised of experts regarded as industry thought leaders in healthcare worldwide.
The organization also provides resources like the Product Library and the DTx Evaluation Toolkit for stakeholders to have better knowledge of digital therapeutics and to improve their practices in the healthcare landscape.
This resource helps key stakeholders understand and differentiate digital therapeutics from the thousands of other mobile health apps that are available, DTA developed this library to highlight evidence-based innovative DTx products.
The products in this library are currently on the market and meet the definition of a DTx product and attest to aligning with industry Core Principles.
DTx Evaluation Toolkit
As healthcare decision makers (HCDMs) across the world seek out, assess, approve, and implement DTx products, it is important for these clinicians, policymakers, and payors to have access to reliable resources and frameworks that enable more consistent evaluation and implementation of DTx products across local, national, and regional settings.
